Preprint · 2026 · Open access

Targeting tankyrase scaffolding in the β-catenin destruction complex by PROTAC overcomes the limitation of catalytic inhibitors in colorectal cancer

Qian Wang, Liping Li, Lin You, Shuai Wang, Lei Han, Bingnan Wang, Liping Yao, Yesu Addepalli, Yong De Lu, Ilgen Mender, Ann Marie Flusché, Chiho Kim and 6 more

eLife, 14, RP109052 · Published 4 November 2026 · DOI 10.7554/elife.109052

Open full textCite this paper

In brief

“Targeting tankyrase scaffolding in the β-catenin destruction complex by PROTAC overcomes the limitation of catalytic inhibitors in colorectal cancer” is a 2026 preprint by Qian Wang and 17 co-authors, published in eLife. OpenAlex counts 1 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at eLife.

Citations
1
Most cited in
2025 (1)
References
79
Authors
18

Abstract

Aberrant WNT/β-catenin signaling drives tumorigenesis and metastasis in cancer. Although enzymatic inhibitors of tankyrase (TNKS) effectively block AXIN degradation and stabilize the β-catenin destruction complex (DC), they have demonstrated limited efficacy in various colorectal cancer (CRC) models. Here, we demonstrate that, unexpectedly, the induction of AXIN puncta represents a major barrier to achieving therapeutic efficacy. Mechanistically, catalytic inhibition of TNKS prevents TNKS turnover and drives its accumulation in the DC, wherein the scaffolding function of TNKS induces AXIN puncta formation, rigidifies the DC, and impedes β-catenin turnover. Chemically induced degradation of TNKS overcomes this limitation by stabilizing AXIN without puncta formation, providing a deeper suppression of the WNT/β-catenin pathway activity and the proliferation of CRC cells harboring dysfunctional APC mutations. Collectively, these findings provide an explanation for the unsatisfactory outcomes of drugging the WNT/β-catenin signaling pathway by TNKS inhibitors and highlight TNKS degradation as a promising approach to treat WNT/β-catenin-driven CRC.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Wang, Q., Li, L., You, L., Wang, S., Han, L., Wang, B., Yao, L., Addepalli, Y., De Lu, Y., Mender, I., Flusché, A. M., Kim, C., Yarravarapu, N., Lemoff, A. S., Lum, L., Shay, J. W., Yu, Y., & Chen, C. (2026). Targeting tankyrase scaffolding in the β-catenin destruction complex by PROTAC overcomes the limitation of catalytic inhibitors in colorectal cancer. eLife, 14, RP109052. https://doi.org/10.7554/elife.109052

MLA 9

Wang, Qian, et al. “Targeting tankyrase scaffolding in the β-catenin destruction complex by PROTAC overcomes the limitation of catalytic inhibitors in colorectal cancer.” eLife, vol. 14, 2026, p. RP109052. https://doi.org/10.7554/elife.109052.

Chicago

Wang, Qian, Liping Li, Lin You, Shuai Wang, Lei Han, Bingnan Wang, Liping Yao, et al. 2026. “Targeting tankyrase scaffolding in the β-catenin destruction complex by PROTAC overcomes the limitation of catalytic inhibitors in colorectal cancer.” eLife 14: RP109052. https://doi.org/10.7554/elife.109052.

Harvard

Wang, Q. et al. (2026) ‘Targeting tankyrase scaffolding in the β-catenin destruction complex by PROTAC overcomes the limitation of catalytic inhibitors in colorectal cancer’, eLife, 14, p. RP109052. doi:10.7554/elife.109052.

IEEE

Q. Wang et al., “Targeting tankyrase scaffolding in the β-catenin destruction complex by PROTAC overcomes the limitation of catalytic inhibitors in colorectal cancer,” eLife, vol. 14, p. RP109052, 2026, doi: 10.7554/elife.109052.

BibTeX

@misc{wang2026targeting,
  title     = {{Targeting tankyrase scaffolding in the β-catenin destruction complex by PROTAC overcomes the limitation of catalytic inhibitors in colorectal cancer}},
  author    = {Wang, Qian and Li, Liping and You, Lin and Wang, Shuai and Han, Lei and Wang, Bingnan and Yao, Liping and Addepalli, Yesu and De Lu, Yong and Mender, Ilgen and Flusché, Ann Marie and Kim, Chiho and Yarravarapu, Nageswari and Lemoff, Andrew S. and Lum, Lawrence and Shay, Jerry W. and Yu, Yonghao and Chen, Chuo},
  howpublished = {eLife},
  year      = {2026},
  volume    = {14},
  pages     = {RP109052},
  doi       = {10.7554/elife.109052},
  url       = {https://doi.org/10.7554/elife.109052}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer

  • tankyrase
  • PROTACs
  • β-catenin destruction complex
  • colorectal cancer
  • Wnt/β-catenin signaling
  • APC mutation
  • protein degradation

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Wang, Q., Li, L., You, L., Wang, S., Han, L., Wang, B., Yao, L., Addepalli, Y., De Lu, Y., Mender, I., Flusché, A. M., Kim, C., Yarravarapu, N., Lemoff, A. S., Lum, L., Shay, J. W., Yu, Y., & Chen, C. (2026). Targeting tankyrase scaffolding in the β-catenin destruction complex by PROTAC overcomes the limitation of catalytic inhibitors in colorectal cancer. eLife, 14, RP109052. https://doi.org/10.7554/elife.109052

How many times has this paper been cited?

1 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at eLife: sign in and open the full text from this page.

Who wrote this paper?

Qian Wang, Liping Li, Lin You, Shuai Wang, Lei Han, Bingnan Wang, Liping Yao, Yesu Addepalli, Yong De Lu, Ilgen Mender, Ann Marie Flusché, Chiho Kim and 6 more.

What is the DOI of this paper?

10.7554/elife.109052, permanently at https://doi.org/10.7554/elife.109052. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.